To diagnose the presence of the pathologic observation of Alzheimer's disease and other brain diseases and the severity and progress of the diseases by the brain tomography using a specific radioactive labeling compound.
A positron-emitting labeling compound of the formula [Q is (CH2)m, O or the like; X is O or S; Y is (CH2)m; L is a (substituted)phenyl or the like; R1 is H or a 1-6C alkyl; (m) is 1-3] {e.g.5,7-dihydro-7-[11C]- methyl-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2- benzisoxazol-6-one} and its pharmacologically permissible salt is injected into the blood flow of human and the brain is imaged by a positron-emitting tomography or a single photon emission computed tomography to form a brain image showing the position and relative amount of acetylcholinesterase. The presence and severity of Alzheimer's disease can be diagnosed by comparing the image with the image of normal brain.
DANNALS ROBERT F
FROST J JAMES
MUSACHIO JOHN
SCHEFFEL URSULA
VILLALOBOS ANABELLA
